A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif) Therapy for Korean Patients With Multiple Sclerosis.

Trial Profile

A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif) Therapy for Korean Patients With Multiple Sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2014

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 09 Aug 2012 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
    • 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top